News

Higher Medicine Announces Strategic Investment by Cerdwen to Accelerate Therapies for Kabuki Syndrome and Other Brain Disorders

Higher Medicine Inc.  announced a strategic investment and fundraising partnership with Cerdwen, a venture capital firm focused on health and performance technology innovation.

Based in West Chester, Pennsylvania, Cerdwen partners with visionary founders to advance transformative healthcare technologies, supporting the translation of bold scientific ideas into meaningful clinical and commercial impact.

“Higher Medicine exemplifies the type of company we seek to partner with: rigorous science, a focused initial indication, and a platform capable of expanding into significant unmet medical needs,” said Kevin Brophy, Managing Principal of Cerdwen. “Dr. Kim and his team are tackling complex CNS disorders with a differentiated epigenetic approach, and we believe the company is well-positioned to translate that ambition into clinical impact.”

“Higher Medicine was founded on a simple but ambitious belief: that many devastating brain disorders need not be lifelong sentences,” said Dr. Leo Kim, Founder and CEO of Higher Medicine. “By harnessing epigenetic biology, we aim to prevent, slow, or even reverse conditions that few companies are willing to confront. Our initial focus on Kabuki syndrome is a deliberate entry point into a broader platform that can be extended to multiple high-unmet-need CNS indications such as CTE and Alzheimer’s disease. With Cerdwen’s investment, we will heighten the momentum for the seed round and accelerate toward clinical proof-of-concept.”

“This investment represents a strong validation of Higher Medicine’s scientific vision and execution,” said Marie Mazur, Board Member of the Mid-Atlantic Diamond Venture (MADV). “It also highlights the power of MADV’s regional biotech network and quarterly Forums, as this partnership originated from our December pitch event.”

The investment was completed via a Simple Agreement for Future Equity (SAFE) and closed on December 31, 2025. The transaction advances Higher Medicine’s Seed Expansion financing and marks a key milestone toward first-in-human clinical studies.

Read more here.

Recent News

06/02/2026

TearSolutions Receives FDA Orphan Drug and Fast Track Designations for Lacripep® in Neurotrophic Keratitis and Initiates Phase 2 Clinical Trial with First Patients Dosed

TearSolutions, Inc. (“TearSolutions”), a clinical-stage biotechnology company developing novel ophthalmic therapeutics, today announced receiving Food and Drug Administration (FDA) Orphan Drug (ODD) and Fast Track Designations for Lacripep in Neurotrophic Keratitis (NK) and initiating a Phase 2 clinical trial with first patients dosed. The FDA’s ODD provides incentives, including tax credits for clinical testing and

06/02/2026

Contraline Announces $92.5 Million Series B Financing to Advance NES/T Male Contraceptive into Late-Stage Development

Contraline, Inc., a clinical-stage biopharmaceutical company developing novel male contraceptives, today announced the closing of a $92.5 million Series B financing co-led by BVF Partners L.P. and RA Capital Management, with participation from GV (Google Ventures), Lumira Ventures, Invus, and other new and existing investors. In conjunction with the closing of the Series B financing,

06/02/2026

GEN Names BioHealth Capital Region a Top 3 U.S. Biopharma Cluster for Fourth Year in a Row

The BioHealth Capital Region, spanning Maryland, Virginia, and Washington, D.C., has once again been named one of the nation’s Top 3 biopharma clusters by Genetic Engineering & Biotechnology News (GEN), marking the region’s fourth consecutive year in the Top 3. GEN’s 2026 “Top 10 U.S. Biopharma Clusters” ranking was authored by Alex Philippidis, Senior Business